Stockreport

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency [Yahoo! Finance]

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF CTA approval for ECUR-506 in the United Kingdom provides further regulatory support for Precision BioSciences' ARCUS in vivo gene editing platform DURHAM, N.C., March [Read more]